Apixaban versus Warfarin in Patients with Atrial Fibrillation
Top Cited Papers
Open Access
- 15 September 2011
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 365 (11), 981-992
- https://doi.org/10.1056/nejmoa1107039
Abstract
Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin.Keywords
This publication has 14 references indexed in Scilit:
- Apixaban with Antiplatelet Therapy after Acute Coronary SyndromeThe New England Journal of Medicine, 2011
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationCirculation, 2011
- Apixaban in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationaleAmerican Heart Journal, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009
- The Role of Tissue Factor and Factor VIIa in HemostasisAnesthesia & Analgesia, 2009
- Apixaban Metabolism and Pharmacokinetics after Oral Administration to HumansDrug Metabolism and Disposition, 2008
- Antithrombotic drug development for atrial fibrillation: Proceedings, Washington, DC, July 25-27, 2005American Heart Journal, 2008
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Antithrombotic Therapy To Prevent Stroke in Patients with Atrial FibrillationAnnals of Internal Medicine, 1999